Dr. Valerie Odegard Ph.D. is the Pres & Chief Scientific Officer at Silverback Therapeutics.
As the Pres & Chief Scientific Officer of Silverback Therapeutics, the total compensation of Dr D at Silverback Therapeutics is $552,384. There are 1 executives at Silverback Therapeutics getting paid more, with Dr. Laura K. Shawver having the highest compensation of $786,653.
Dr D is 44, he's been the Pres & Chief Scientific Officer of Silverback Therapeutics since . There are 4 older and no younger executives at Silverback Therapeutics. The oldest executive at Silverback Therapeutics, Inc. is Dr. Laura K. Shawver, 63, who is the CEO & Director.
Valerie's mailing address filed with the SEC is C/O SILVERBACK THERAPEUTICS, INC., 500 FAIRVIEW AVENUE N, SUITE 600, SEATTLE, WA, 98109.
Over the last 6 years, insiders at Silverback Therapeutics have traded over $0 worth of Silverback Therapeutics stock and bought 2,785,936 units worth $58,491,063 . The most active insiders traders include Peter A. Thompson, Thilo Schroeder и Advisors Llc Orbi Med Capit.... On average, Silverback Therapeutics executives and independent directors trade stock every 60 days with the average trade being worth of $1,681,567. The most recent stock trade was executed by Laura Shawver on 5 August 2022, trading 78,740 units of SBTX stock currently worth $100,000.
Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers. The company also focuses on developing SBT6290, a product candidate that is in preclinical stage, which is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in bladder, triple negative breast, head and neck, and non-small cell lung cancers. In addition, it engages in developing SBT8230, a TLR8 linker-payload conjugated to an ASGR1 monoclonal antibody that is under development for the treatment of chronic hepatitis B virus infection; and agents that localize therapies to modulate pathways in additional oncology and fibrosis indications using TLR8 and other linker-payloads. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Silverback Therapeutics executives and other stock owners filed with the SEC include: